Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Caribou Biosciences (CRBU) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to -1,250.91%.

  • Caribou Biosciences' EBITDA Margin rose 40798.00% to -1,250.91% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,697.93%, marking a year-over-year decrease of 42255.00%. This contributed to the annual value of -1,489.69% for FY2024, which is 119813.00% down from last year.
  • As of Q3 2025, Caribou Biosciences' EBITDA Margin stood at -1,250.91%, which was up 38.48% from -2,033.18% recorded in Q2 2025.
  • Caribou Biosciences' 5-year EBITDA Margin high stood at -41.62% for Q3 2023, and its period low was -2,033.18% during Q2 2025.
  • In the last 3 years, Caribou Biosciences' EBITDA Margin had a median value of -1,250.91% in 2025 and averaged -1,249.02%.
  • Per our database at Business Quant, Caribou Biosciences' EBITDA Margin surged by 81,844bps in 2021 and then tumbled by 161,728bps in 2024.
  • Quarterly analysis of 5 years shows Caribou Biosciences' EBITDA Margin stood at -727.39% in 2021, then skyrocketed by 1,038bps to -717.01% in 2022, then tumbled by 22,436bps to -941.37% in 2023, then tumbled by 79,305bps to -1,734.42% in 2024, then skyrocketed by 40,798bps to -1,250.91% in 2025.
  • Its last three reported values are -1,250.91% in Q3 2025, -2,033.18% for Q2 2025, and -1,703.31% during Q1 2025.